Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	20739
Country	United States

Received	2015-06-19 08:39
Peer-Review Started	2015-06-20 17:19
To Make the First Decision	2015-07-27 18:35
Return for Revision	2015-07-31 17:11
Revised	2015-08-14 23:06
Second Decision	2015-09-10 08:22
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-09-18 14:16
Articles in Press	2015-09-18 14:16
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-10-26 15:13
Publish the Manuscript Online	2015-11-17 08:51

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Novel therapy for advanced gastric cancer
Manuscript Source	Invited Manuscript
All Author List	Yue Zhang and Shenhong Wu
Funding Agency and Grant Number
Corresponding Author	Yue Zhang, MD, MPH, Assistant Professor, Division of Hematology and Oncology, Stony Brook University, HSC 15-040, 101 Nicholls Rd, Stony Brook, NY 11794-8151, United States. yue.zhang@stonybrookmedicine.edu
Key Words	Gastric cancer; Novel therapy; Targeted therapy; Immune therapy; Gastric cancer stem cell
Core Tip	Advanced gastric cancer (GC) has very poor outcome with chemotherapy remains the main treatment. There is an urgent unmet need to develop novel therapy for GC. Limited success is achieved for targeted therapy after trastuzumab for human epidermal growth factor receptor 2 positive disease. Ramucirumab was recently approved by Food and Drug Administration as a single agent or combined with paclitaxel in refractory advanced GC patients. Immune therapy and GC stem cell research are on the horizon.
Publish Date	2015-11-17 08:51
Citation	Zhang Y, Wu S. Novel therapy for advanced gastric cancer. World J Gastrointest Oncol 2015; 7(11): 263-270
URL	http://www.wjgnet.com/1948-5204/full/v7/i11/263.htm
DOI	http://dx.doi.org/10.4251/wjgo.v7.i11.263

Full Article (PDF)	WJGO-7-263.pdf
Full Article (Word)	WJGO-7-263.doc
Manuscript File	20739-Review.docx
Answering Reviewers	20739-Answering reviewers.pdf
Audio Core Tip	20739-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	20739-Conflict-of-interest statement.pdf
Copyright License Agreement	20739-Copyright assignment.pdf
Peer-review Report	20739-Peer-review(s).pdf
Scientific Misconduct Check	20739-Scientific misconduct check.pdf
Scientific Editor Work List	20739-Scientific editor work list.pdf